Hospital-acquired infection

Last updated

Nosocomial infection
Other namesHAI (Healthcare-Associated Infections)
Contaminated surfaces increase cross-transmission.jpg
Contaminated surfaces increase cross-transmission
Specialty Infectious disease

A hospital-acquired infection, also known as a nosocomial infection (from the Greek nosokomeion, meaning "hospital"), is an infection that is acquired in a hospital or other healthcare facility. [1] To emphasize both hospital and nonhospital settings, it is sometimes instead called a healthcare-associated infection. [2] Such an infection can be acquired in a hospital, nursing home, rehabilitation facility, outpatient clinic, diagnostic laboratory or other clinical settings. A number of dynamic processes can bring contamination into operating rooms and other areas within nosocomial settings. [3] [4] Infection is spread to the susceptible patient in the clinical setting by various means. Healthcare staff also spread infection, in addition to contaminated equipment, bed linens, or air droplets. The infection can originate from the outside environment, another infected patient, staff that may be infected, or in some cases, the source of the infection cannot be determined. In some cases the microorganism originates from the patient's own skin microbiota, becoming opportunistic after surgery or other procedures that compromise the protective skin barrier. Though the patient may have contracted the infection from their own skin, the infection is still considered nosocomial since it develops in the health care setting. [5] The term nosocomial infection is used when there is a lack of evidence that the infection was present when the patient entered the healthcare setting, thus meaning it was acquired or became problematic post-admission. [5] [6]

Contents

Effects

During 2002 in the United States, the Centers for Disease Control and Prevention estimated that roughly 1.7 million healthcare-associated infections, from all types of microorganisms, including bacteria and fungi combined, caused or contributed to 99,000 deaths. [7] In Europe, where hospital surveys have been conducted, the category of gram-negative infections are estimated to account for two-thirds of the 25,000 deaths each year. [8] Nosocomial infections can cause severe pneumonia and infections of the urinary tract, bloodstream and other parts of the body. [9] [10] Many types display antimicrobial resistance, which can complicate treatment. [11]

In the UK about 300,000 patients were affected in 2017, and this was estimated to cost the NHS about £1 billion a year. [12]

Types

Organisms

Cause

Transmission

In-dwelling catheters have recently been identified with hospital-acquired infections. [14] To deal with this complication, procedures are used, called intravascular antimicrobial lock therapy, that can reduce infections that are unexposed to blood-borne antibiotics. [15] Introducing antibiotics, including ethanol, into the catheter (without flushing it into the bloodstream) reduces the formation of biofilms. [13]

Main routes of transmission
RouteDescription
Contact transmissionThe most important and frequent mode of transmission of nosocomial infections is by direct contact.
Droplet transmissionTransmission occurs when droplets containing microbes from the infected person are propelled a short distance through the air and deposited on the patient's body; droplets are generated from the source person mainly by coughing, sneezing, and talking, and during the performance of certain procedures, such as bronchoscopy.
Airborne transmission Dissemination can be either airborne droplet nuclei (small-particle residue {5 μm or smaller in size} of evaporated droplets containing microorganisms that remain suspended in the air for long periods of time) or dust particles containing the infectious agent. Microorganisms carried in this manner can be dispersed widely by air currents and may become inhaled by a susceptible host within the same room or over a longer distance from the source patient, depending on environmental factors; therefore, special air-handling and ventilation are required to prevent airborne transmission. Microorganisms transmitted by airborne transmission include Legionella , Mycobacterium tuberculosis and the rubeola and varicella viruses.
Common vehicle transmissionThis applies to microorganisms transmitted to the host by contaminated fomite items, such as food, water, medications, devices, and equipment.
Vector borne transmission This occurs when vectors such as mosquitoes, flies, rats, and other vermin transmit microorganisms.

Contact transmission is divided into two subgroups: direct-contact transmission and indirect-contact transmission.

Routes of contact transmission
RouteDescription
Direct-contact transmissionThis involves a direct body surface-to-body surface contact and physical transfer of microorganisms between a susceptible host and an infected or colonized person, such as when a person turns a patient, gives a patient a bath, or performs other patient-care activities that require direct personal contact. Direct-contact transmission also can occur between two patients, with one serving as the source of the infectious microorganisms and the other as a susceptible host.
Indirect-contact transmissionThis involves contact of a susceptible host with a contaminated intermediate object, usually inanimate, such as contaminated instruments, needles, or dressings, or contaminated gloves that are not changed between patients. In addition, the improper use of saline flush syringes, vials, and bags has been implicated in disease transmission in the US, even when healthcare workers had access to gloves, disposable needles, intravenous devices, and flushes. [16]

Patient susceptibility

Alongside reducing vectors for transmission, patient susceptibility to hospital-acquired infections needs to be considered. Factors which render patients at greater risk of infections include:

  1. Receipt of immunosuppressive medications such as glucocorticoids [17] or immunosuppressive drugs as part of treatments for cancer, organ transplantation or autoimmune diseases
  2. Impaired immunity due to diseases such as haematological malignancy, primary immunodeficiency, HIV/AIDS or critical illness, [18] including severe COVID-19 [17] [19]
  3. Presence of indwelling devices which breach natural defences, including endotracheal tubes, central venous catheters and urinary catheters.
  4. The use of antibiotics does not, itself, increase risk of hospital-acquired infections, but does contribute to the prevalence of Antimicrobial resistant organisms amongst patients with hospital-acquired infections [20]

Device-associated infections

Given the association between invasive devices and hospital-acquired infections, specific terms are used to delineate such infections to allow for monitoring and prevention. Noted device-associated infections include ventilator-associated pneumonia, catheter-associated blood stream infections, catheter-associated urinary tract infections and device-associated ventriculitis. Surveillance for these infections is commonly undertaken and reported by bodies such as the European Centre for Disease Prevention and Control and Centers for Disease Control and Prevention.[ citation needed ]

Prevention

Making Health Care Safer-CDC Vital Signs-March 2012.pdf

Controlling nosocomial infection is to implement QA/QC measures to the health care sectors, and evidence-based management can be a feasible approach. For those with ventilator-associated or hospital-acquired pneumonia, controlling and monitoring hospital indoor air quality needs to be on agenda in management, [21] whereas for nosocomial rotavirus infection, a hand hygiene protocol has to be enforced. [22] [23] [24]

To reduce the number of hospital-acquired infections, the state of Maryland implemented the Maryland Hospital-Acquired Conditions Program that provides financial rewards and penalties for individual hospitals. An adaptation of the Centers for Medicare & Medicaid Services payment policy causes poor-performing hospitals to lose up to 3% of their inpatient revenues, whereas hospitals that are able to decrease hospital-acquired infections can earn up to 3% in rewards. During the program's first two years, complication rates fell by 15.26% across all hospital-acquired conditions tracked by the state (including those not covered by the program), from a risk-adjusted complication rate of 2.38 per 1,000 people in 2009 to a rate of 2.02 in 2011. The 15.26% decline translates into more than $100 million in cost savings for the health care system in Maryland, with the largest savings coming from avoidance of urinary tract infections, sepsis and other severe infections, and pneumonia and other lung infections. If similar results could be achieved nationwide, the Medicare program would save an estimated $1.3 billion over two years, while the US healthcare system as a whole would save $5.3 billion. [25]

Sanitation

Hospitals have sanitation protocols regarding uniforms, equipment sterilization, washing, and other preventive measures. Thorough hand washing and/or use of alcohol rubs by all medical personnel before and after each patient contact is one of the most effective ways to combat nosocomial infections. [26] More careful use of antimicrobial agents, such as antibiotics, is also considered vital. [27] As many hospital-acquired infections caused by bacteria such as methicillin-resistant Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus, and Clostridioides difficile are caused by a breach of these protocols, it is common that affected patients make medical negligence claims against the hospital in question. [28]

Sanitizing surfaces is part of control measures to reduce nosocomial infections in healthcare environments. Modern sanitizing methods such as Non-flammable Alcohol Vapor in Carbon Dioxide systems have been effective against gastroenteritis, methicillin-resistant Staphylococcus aureus, and influenza agents. The use of hydrogen peroxide vapor has been clinically proven to reduce infection rates and risk of acquisition. Hydrogen peroxide is effective against endospore-forming bacteria, such as Clostridioides difficile, whereas alcohol is ineffective. [29] [ non-primary source needed ] Ultraviolet cleaning devices may also be used to disinfect the rooms of patients infected with Clostridioides difficile or methicillin-resistant Staphylococcus aureus after discharge. [30] [ non-primary source needed ]

Despite sanitation protocol, patients cannot be entirely isolated from infectious agents. Furthermore, patients are often prescribed antibiotics and other antimicrobial drugs to help treat illness; this may increase the selection pressure for the emergence of resistant strains. [31]

Sterilization

Sterilization goes further than just sanitizing. It kills all microorganisms on equipment and surfaces through exposure to chemicals, ionizing radiation, dry heat, or steam under pressure. [32]

Isolation

Isolation is the implementation of isolating precautions designed to prevent transmission of microorganisms by common routes in hospitals. (See Universal precautions and Transmission-based precautions.) Because agent and host factors are more difficult to control, interruption of transfer of microorganisms is directed primarily at transmission for example isolation of infectious cases in special hospitals and isolation of patient with infected wounds in special rooms also isolation of joint transplantation patients on specific rooms.[ citation needed ]

Handwashing

Handwashing frequently is called the single most important measure to reduce the risks of transmitting skin microorganisms from one person to another or from one site to another on the same patient. Washing hands as promptly and thoroughly as possible between patient contacts and after contact with blood, body fluids, secretions, excretions, and equipment or articles contaminated by them is an important component of infection control and isolation precautions. The spread of nosocomial infections, among immunocompromised patients is connected with health care workers' hand contamination in almost 40% of cases, and is a challenging problem in the modern hospitals. The best way for workers to overcome this problem is conducting correct hand-hygiene procedures; this is why the WHO launched in 2005 the GLOBAL Patient Safety Challenge. [33]

Two categories of micro-organisms can be present on health care workers' hands: transient flora and resident flora. The first is represented by the micro-organisms taken by workers from the environment, and the bacteria in it are capable of surviving on the human skin and sometimes to grow. The second group is represented by the permanent micro-organisms living on the skin surface (on the stratum corneum or immediately under it). They are capable of surviving on the human skin and to grow freely on it. They have low pathogenicity and infection rate, and they create a kind of protection from the colonization from other more pathogenic bacteria. The skin of workers is colonized by 3.9 × 104 – 4.6 × 106 cfu/cm2. The microbes comprising the resident flora are: Staphylococcus epidermidis , Staphylococcus hominis, and Micrococcus, Propionibacterium, Corynebacterium, Dermabacter, and Pittosporum spp., while transient organisms are Staphylococcus aureus, and Klebsiella pneumoniae, and Acinetobacter, Enterobacter and Candida spp. The goal of hand hygiene is to eliminate the transient flora with a careful and proper performance of hand washing, using different kinds of soap, (normal and antiseptic), and alcohol-based gels. The main problems found in the practice of hand hygiene is connected with the lack of available sinks and time-consuming performance of hand washing. An easy way to resolve this problem could be the use of alcohol-based hand rubs, because of faster application compared to correct hand-washing. [34]

Improving patient hand washing has also been shown to reduce the rate of nosocomial infection. Patients who are bed-bound often do not have as much access to clean their hands at mealtimes or after touching surfaces or handling waste such as tissues. By reinforcing the importance of handwashing and providing sanitizing gel or wipes within reach of the bed, nurses were directly able to reduce infection rates. A study published in 2017 demonstrated this by improving patient education on both proper hand-washing procedure and important times to use sanitizer and successfully reduced the rate of enterococci and Staphylococcus aureus. [35]

All visitors must follow the same procedures as hospital staff to adequately control the spread of infections. Moreover, multidrug-resistant infections can leave the hospital and become part of the community flora if steps are not taken to stop this transmission.[ citation needed ]

It is unclear whether or not nail polish or rings affected surgical wound infection rates. [36]

Gloves

In addition to hand washing, gloves play an important role in reducing the risks of transmission of microorganisms. Gloves are worn for three important reasons in hospitals. First, they are worn to provide a protective barrier for personnel, preventing large scale contamination of the hands when touching blood, body fluids, secretions, excretions, mucous membranes, and non-intact skin. In the United States, the Occupational Safety and Health Administration has mandated wearing gloves to reduce the risk of bloodborne pathogen infections. [37] Second, gloves are worn to reduce the likelihood that microorganisms present on the hands of personnel will be transmitted to patients during invasive or other patient-care procedures that involve touching a patient's mucous membranes and nonintact skin. Third, they are worn to reduce the likelihood that the hands of personnel contaminated with micro-organisms from a patient or a fomite can transmit those micro-organisms to another patient. In this situation, gloves must be changed between patient contacts, and hands should be washed after gloves are removed.[ citation needed ]

Antimicrobial surfaces

Micro-organisms are known to survive on inanimate "touch" surfaces for extended periods of time. [38] [39] This can be especially troublesome in hospital environments where immunodeficient patients are at enhanced risk for contracting nosocomial infections. Patients with hospital-acquired infections are predominantly hospitalized in different types of intensive care units (ICUs). [40]

Touch surfaces commonly found in hospital rooms, such as bed rails, call buttons, touch plates, chairs, door handles, light switches, grab rails, intravenous poles, dispensers (alcohol gel, paper towel, soap), dressing trolleys, and counter and table tops are known to be contaminated with Staphylococcus , methicillin-resistant Staphylococcus aureus (one of the most virulent strains of antibiotic-resistant bacteria) and vancomycin-resistant Enterococcus. [41] Objects in closest proximity to patients have the highest levels of methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus. This is why touch surfaces in hospital rooms can serve as sources, or reservoirs, for the spread of bacteria from the hands of healthcare workers and visitors to patients. [42]

A number of compounds can decrease the risk of bacteria growing on surfaces including: copper, silver, and germicides. [43]

There have been a number of studies evaluating the use of no-touch cleaning systems particularly the use of ultraviolet C devices. One review was inconclusive due to lack of, or of poor quality evidence. [44] Other reviews have found some evidence, and growing evidence of their effectiveness. [45] [46]

Treatment

Two of the bacteria species most likely to infect patients are the Gram-positive strains of methicillin-resistant Staphylococcus aureus, and Gram-negative Acinetobacter baumannii . While antibiotic drugs to treat diseases caused by methicillin-resistant Staphylococcus aureus are available, few effective drugs are available for Acinetobacter. Acinetobacter bacteria are evolving and becoming immune to antibiotics, so in many cases, polymyxin-type antibacterials need to be used. "In many respects it's far worse than MRSA", said a specialist at Case Western Reserve University. [47]

Another growing disease, especially prevalent in New York City hospitals, is the drug-resistant, Gram-negative Klebsiella pneumoniae . An estimated more than 20% of the Klebsiella infections in Brooklyn hospitals "are now resistant to virtually all modern antibiotics, and those supergerms are now spreading worldwide." [47]

The bacteria, classified as Gram-negative because of their color on the Gram stain, can cause severe pneumonia and infections of the urinary tract, bloodstream, and other parts of the body. Their cell structures make them more difficult to attack with antibiotics than Gram-positive organisms like methicillin-resistant Staphylococcus aureus. In some cases, antibiotic resistance is spreading to Gram-negative bacteria that can infect people outside the hospital. "For gram-positives we need better drugs; for gram-negatives we need any drugs", said Brad Spellberg, an infectious-disease specialist at Harbor–UCLA Medical Center, and the author of Rising Plague, a book about drug-resistant pathogens. [47]

Hospital-acquired pneumonia (HAP) is the second most common nosocomial infection and accounts for approximately one-fourth of all infections in the intensive care unit (ICU). [48] HAP, or nosocomial pneumonia, is a lower respiratory infection that was not incubating at the time of hospital admission and that presents clinically two or more days after hospitalization. [49] Ventilator-associated pneumonia (VAP) is defined as HAP in patients receiving mechanical ventilation. The incidence of VAP is 10–30% among patients who require mechanical ventilation for >48 h. [50] A standard treatment protocol is based on accurate diagnosis definitions, microbiological confirmation of VAP, and the administration of imipenem plus ciprofloxacin as initial empirical antibiotic treatment. [51]

One-third of nosocomial infections are considered preventable. The CDC estimates 687,000 people in the United States were infected by hospital-acquired infections in 2015, resulting in 72,000 deaths. [52] The most common nosocomial infections are of the urinary tract, surgical site and various pneumonias. [7]

An alternative treatment targeting localised infections is the use of irradiation by ultraviolet C. [53]

Epidemiology

The methods used differ from country to country (definitions used, type of nosocomial infections covered, health units surveyed, inclusion or exclusion of imported infections, etc.), so the international comparisons of nosocomial infection rates should be made with the utmost care.[ citation needed ]

Belgium

In Belgium, the prevalence of nosocomial infections is about 6.2%. Annually about 125,500 patients become infected by a nosocomial infection, resulting in almost 3000 deaths. The extra costs for the health insurance are estimated to be approximately €400 million/year. [54]

France

Estimates ranged from 6.7% in 1990 to 7.4% (patients may have several infections). [55] At national level, prevalence among patients in health care facilities was 6.7% in 1996, [56] 5.9% in 2001 [57] and 5.0% in 2006. [58] The rates for nosocomial infections were 7.6% in 1996, 6.4% in 2001 and 5.4% in 2006.[ citation needed ]

In 2006, the most common infection sites were urinary tract infections (30.3%), pneumopathy (14.7%), infections of surgery site (14.2%). Infections of the skin and mucous membrane (10.2%), other respiratory infections (6.8%) and bacterial infections / blood poisoning (6.4%). [59] The rates among adult patients in intensive care were 13.5% in 2004, 14.6% in 2005, 14.1% in 2006 and 14.4% in 2007. [60]

Nosocomial infections are estimated to make patients stay in the hospital for four to five additional days. Around 2004–2005, about 9,000 people died each year with a nosocomial infection, of which about 4,200 would have survived without this infection. [61]

Finland

Rate was estimated at 8.5% of patients in 2005. [62]

Italy

Since 2000, estimates show about a 6.7% infection rate, i.e. between 450,000 and 700,000 patients, which caused between 4,500 and 7,000 deaths. [63] A survey in Lombardy gave a rate of 4.9% of patients in 2000. [64]

Switzerland

Estimates range between 2 and 14%. [65] A national survey gave a rate of 7.2% in 2004. [66]

United Kingdom

In 2012, the Health Protection Agency reported the prevalence rate of hospital-acquired infections in England was 6.4% in 2011, against a rate of 8.2% in 2006, [67] with respiratory tract, urinary tract and surgical site infections the most common types of infections reported. [67] In 2018, it was reported that in-hospital infections had risen from 5,972 in 2008 to 48,815 in 2017. [68]

United States

The Centers for Disease Control and Prevention (CDC) estimated roughly 1.7 million hospital-associated infections, from all types of bacteria combined, cause or contribute to 99,000 deaths each year. [69] Other estimates indicate 10%, or 2 million, patients a year become infected, with the annual cost ranging from $4.5 billion to $11 billion. [70] In the US, the most frequent type of hospital infection is urinary tract infection (36%), followed by surgical site infection (20%), and bloodstream infection and pneumonia (both 11%). [47] [ needs update ]

History

Mortality rates 1841-1846 in two clinics documented by Semmelweis Yearly mortality rates 1841-1846 two clinics.png
Mortality rates 1841–1846 in two clinics documented by Semmelweis

In 1841, Ignaz Semmelweis, a Hungarian obstetrician was working at a Vienna maternity hospital. He was "shocked" by the death rate of women who developed puerperal fever. He documented that mortality was three times higher in the ward where the medical students were delivering babies than in the next ward that was staffed by midwifery students. [71] The medical students were also routinely working with cadavers. He compared the rates of infection with a similar hospital in Dublin, Ireland, and hypothesized that it was the medical students who somehow were infecting the women after labor. He instituted mandatory hand-washing in May 1847 and infection rates dropped dramatically. Louis Pasteur proposed the germ theory of disease and began his work on cholera in 1865 by identifying that it was microorganisms that were associated with disease. [72] [73]

See also

Related Research Articles

<i>Staphylococcus aureus</i> Species of gram-positive bacterium

Staphylococcus aureus is a gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin. It is often positive for catalase and nitrate reduction and is a facultative anaerobe, meaning that it can grow without oxygen. Although S. aureus usually acts as a commensal of the human microbiota, it can also become an opportunistic pathogen, being a common cause of skin infections including abscesses, respiratory infections such as sinusitis, and food poisoning. Pathogenic strains often promote infections by producing virulence factors such as potent protein toxins, and the expression of a cell-surface protein that binds and inactivates antibodies. S. aureus is one of the leading pathogens for deaths associated with antimicrobial resistance and the emergence of antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA). The bacterium is a worldwide problem in clinical medicine. Despite much research and development, no vaccine for S. aureus has been approved.

Methicillin-resistant <i>Staphylococcus aureus</i> Bacterium responsible for difficult-to-treat infections in humans

Methicillin-resistant Staphylococcus aureus (MRSA) is a group of gram-positive bacteria that are genetically distinct from other strains of Staphylococcus aureus. MRSA is responsible for several difficult-to-treat infections in humans. It caused more than 100,000 deaths worldwide attributable to antimicrobial resistance in 2019.

Bloodstream infections (BSIs) are infections of blood caused by blood-borne pathogens. The detection of microbes in the blood is always abnormal. A bloodstream infection is different from sepsis, which is characterized by severe inflammatory or immune responses of the host organism to pathogens.

<i>Klebsiella pneumoniae</i> Species of bacterium

Klebsiella pneumoniae is a Gram-negative, non-motile, encapsulated, lactose-fermenting, facultative anaerobic, rod-shaped bacterium. It appears as a mucoid lactose fermenter on MacConkey agar.

Vancomycin-resistant <i>Staphylococcus aureus</i> Antibiotica resistant bacteria

Vancomycin-resistant Staphylococcus aureus (VRSA) are strains of Staphylococcus aureus that have acquired resistance to the glycopeptide antibiotic vancomycin. Bacteria can acquire resistant genes either by random mutation or through the transfer of DNA from one bacterium to another. Resistance genes interfere with the normal antibiotic function and allow bacteria to grow in the presence of the antibiotic. Resistance in VRSA is conferred by the plasmid-mediated vanA gene and operon. Although VRSA infections are uncommon, VRSA is often resistant to other types of antibiotics and a potential threat to public health because treatment options are limited. VRSA is resistant to many of the standard drugs used to treat S. aureus infections. Furthermore, resistance can be transferred from one bacterium to another.

<span class="mw-page-title-main">Carbapenem</span> Class of highly effective antibiotic agents

Carbapenems are a class of very effective antibiotic agents most commonly used for treatment of severe bacterial infections. This class of antibiotics is usually reserved for known or suspected multidrug-resistant (MDR) bacterial infections. Similar to penicillins and cephalosporins, carbapenems are members of the beta-lactam antibiotics drug class, which kill bacteria by binding to penicillin-binding proteins, thus inhibiting bacterial cell wall synthesis. However, these agents individually exhibit a broader spectrum of activity compared to most cephalosporins and penicillins. Furthermore, carbapenems are typically unaffected by emerging antibiotic resistance, even to other beta-lactams.

<span class="mw-page-title-main">Ventilator-associated pneumonia</span> Pneumonia due to use of ventilator

Ventilator-associated pneumonia (VAP) is a type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals. As such, VAP typically affects critically ill persons that are in an intensive care unit (ICU) and have been on a mechanical ventilator for at least 48 hours. VAP is a major source of increased illness and death. Persons with VAP have increased lengths of ICU hospitalization and have up to a 20–30% death rate. The diagnosis of VAP varies among hospitals and providers but usually requires a new infiltrate on chest x-ray plus two or more other factors. These factors include temperatures of >38 °C or <36 °C, a white blood cell count of >12 × 109/ml, purulent secretions from the airways in the lung, and/or reduction in gas exchange.

<span class="mw-page-title-main">Hospital-acquired pneumonia</span> Pneumonia contracted by a hospital patient

Hospital-acquired pneumonia (HAP) or nosocomial pneumonia refers to any pneumonia contracted by a patient in a hospital at least 48–72 hours after being admitted. It is thus distinguished from community-acquired pneumonia. It is usually caused by a bacterial infection, rather than a virus.

<span class="mw-page-title-main">Panton–Valentine leukocidin</span>

Panton–Valentine leukocidin (PVL) is a cytotoxin—one of the β-pore-forming toxins. The presence of PVL is associated with increased virulence of certain strains (isolates) of Staphylococcus aureus. It is present in the majority of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) isolates studied and is the cause of necrotic lesions involving the skin or mucosa, including necrotic hemorrhagic pneumonia. PVL creates pores in the membranes of infected cells. PVL is produced from the genetic material of a bacteriophage that infects Staphylococcus aureus, making it more virulent.

<span class="mw-page-title-main">Ceftobiprole</span> Chemical compound

Ceftobiprole, sold under the brand name Zevtera among others, is a fifth-generation cephalosporin antibacterial used for the treatment of hospital-acquired pneumonia and community-acquired pneumonia. It is marketed by Basilea Pharmaceutica under the brand names Zevtera and Mabelio. Like other cephalosporins, ceftobiprole exerts its antibacterial activity by binding to important penicillin-binding proteins and inhibiting their transpeptidase activity which is essential for the synthesis of bacterial cell walls. Ceftobiprole has high affinity for penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus strains and retains its activity against strains that express divergent mecA gene homologues. Ceftobiprole also binds to penicillin-binding protein 2b in Streptococcus pneumoniae (penicillin-intermediate), to penicillin-binding protein 2x in Streptococcus pneumoniae (penicillin-resistant), and to penicillin-binding protein 5 in Enterococcus faecalis.

<span class="mw-page-title-main">ST8:USA300</span> Strain of bacteria

ST8:USA300 is a strain of community-associated methicillin-resistant Staphylococcus aureus (MRSA) that has emerged as a particularly antibiotic resistant epidemic that is responsible for rapidly progressive, fatal diseases including necrotizing pneumonia, severe sepsis and necrotizing fasciitis. The epidemiology of infections caused by MRSA is rapidly changing: in the past 10 years, infections caused by this organism have emerged in the community. The 2 MRSA clones in the United States most closely associated with community outbreaks, USA400 and USA300, often contain Panton-Valentine leukocidin (PVL) genes and, more frequently, have been associated with skin and soft tissue infections. Outbreaks of community-associated (CA)-MRSA infections have been reported in correctional facilities, among athletic teams, among military recruits, in newborn nurseries, and among sexually active men who have sex with men, CA-MRSA infections now appear to be endemic in many urban regions and cause most MRSA infections.

<span class="mw-page-title-main">Staphylococcal infection</span> Bacterial infection (genus Staphylococcus)

A staphylococcal infection or staph infection is an infection caused by members of the Staphylococcus genus of bacteria.

<span class="mw-page-title-main">Telavancin</span> Pharmaceutical drug

Telavancin is a bactericidal lipoglycopeptide for use in MRSA or other Gram-positive infections. Telavancin is a semi-synthetic derivative of vancomycin.

Antimicrobial copper-alloy touch surfaces can prevent frequently touched surfaces from serving as reservoirs for the spread of pathogenic microbes. This is especially true in healthcare facilities, where harmful viruses, bacteria, and fungi colonize and persist on doorknobs, push plates, handrails, tray tables, tap (faucet) handles, IV poles, HVAC systems, and other equipment. These microbes can sometimes survive on surfaces for more than 30 days.

<span class="mw-page-title-main">Sophoraflavanone G</span> Chemical compound

Sophoraflavanone G is a volatile phytoncide, released into the atmosphere, soil and ground water, by plants of the genus Sophora. Species include Sophora pachycarpa and Sophora exigua, all found to grow within the United States in a variety of soil types, within temperate conditions, no lower than 0 °F. Sophoraflavanone G is released in order to protect the plant against harmful protozoa, bacteria, and fungi. Sophoraflavanone G, also called kushenin, is a flavonoid compound.

Didier Pittet is an infectious diseases expert and the director of the Infection Control Programme and WHO Collaborating Centre on Patient Safety, University Hospital of Geneva, Geneva, Switzerland. Since 2005, Pittet is also the External Lead of the World Health Organization (WHO) Global Patient Safety Challenge "Clean Care is Safer Care" and African Partnerships for Patient Safety.

ESKAPE is an acronym comprising the scientific names of six highly virulent and antibiotic resistant bacterial pathogens including: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. The acronym is sometimes extended to ESKAPEE to include Escherichia coli. This group of Gram-positive and Gram-negative bacteria can evade or 'escape' commonly used antibiotics due to their increasing multi-drug resistance (MDR). As a result, throughout the world, they are the major cause of life-threatening nosocomial or hospital-acquired infections in immunocompromised and critically ill patients who are most at risk. P. aeruginosa and S. aureus are some of the most ubiquitous pathogens in biofilms found in healthcare. P. aeruginosa is a Gram-negative, rod-shaped bacterium, commonly found in the gut flora, soil, and water that can be spread directly or indirectly to patients in healthcare settings. The pathogen can also be spread in other locations through contamination, including surfaces, equipment, and hands. The opportunistic pathogen can cause hospitalized patients to have infections in the lungs, blood, urinary tract, and in other body regions after surgery. S. aureus is a Gram-positive, cocci-shaped bacterium, residing in the environment and on the skin and nose of many healthy individuals. The bacterium can cause skin and bone infections, pneumonia, and other types of potentially serious infections if it enters the body. S. aureus has also gained resistance to many antibiotic treatments, making healing difficult. Because of natural and unnatural selective pressures and factors, antibiotic resistance in bacteria usually emerges through genetic mutation or acquires antibiotic-resistant genes (ARGs) through horizontal gene transfer - a genetic exchange process by which antibiotic resistance can spread.

Decolonization, also bacterial decolonization, is a medical intervention that attempts to rid a patient of an antimicrobial resistant pathogen, such as methicillin-resistant Staphylococcus aureus (MRSA) or antifungal-resistant Candida.

MRSA ST398 is a specific strain of Methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus is a gram-positive, spherical bacterium that can cause a range of infections in humans and animals. And Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that is resistant to many antibiotics. The abbreviation "ST" in MRSA ST398 refers to the sequence type of the bacterium. MRSA ST398 is a clonal complex 398 (CC398). This means that the strain had emerged in a human clinic, without any obvious or understandable causes. MRSA ST398, a specific strain of MRSA, is commonly found in livestock, and can cause infections in humans who come into contact with infected animals.

References

  1. ↑ Rosenthal VD, Bijie H, Maki DG, Mehta Y, Apisarnthanarak A, Medeiros EA, Leblebicioglu H, Fisher D, Álvarez-Moreno C, Khader IA, Martínez MD, Cuellar LE, Navoa-Ng JA, Abouqal R, Garcell HG (June 2012). "International Nosocomial Infection Control Consortium (INICC) report, data summary of 36 countries, for 2004–2009" (PDF). American Journal of Infection Control. 40 (5): 396–407. doi:10.1016/j.ajic.2011.05.020. PMID   21908073.
  2. ↑ "HAI Data and Statistics". cdc.gov. 10 January 2018. Retrieved 13 January 2018.
  3. ↑ Carroll GT, Kirschman DL, Mammana A (2022). "Increased CO2 levels in the operating room correlate with the number of healthcare workers present: An imperative for intentional crowd control". Patient Safety in Surgery. 16 (1): 35. doi: 10.1186/s13037-022-00343-8 . PMC   9672642 . PMID   36397098. S2CID   253556197.
  4. ↑ Carroll GT, Kirschman DL (2022). "Discrete room pressure drops predict door openings and contamination levels in the operating room setting". Perioperative Care and Operating Room Management. 29: 100291. doi: 10.1016/j.pcorm.2022.100291 . S2CID   252640995.
  5. 1 2 Monegro AF, Muppidi V, Regunath H (2020), "Hospital Acquired Infections", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID   28722887 , retrieved 1 February 2021
  6. ↑ Sydnor ER, Perl TM (January 2011). "Hospital epidemiology and infection control in acute-care settings". Clinical Microbiology Reviews. 24 (1): 141–173. doi: 10.1128/CMR.00027-10 . ISSN   1098-6618. PMC   3021207 . PMID   21233510.
  7. 1 2 Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM (2007). "Estimating Healthcare-associated Infections and Deaths in U.S. Hospitals, 2002". Public Health Reports. 122 (2): 160–166. doi: 10.1177/003335490712200205 . PMC   1820440 . PMID   17357358.
  8. ↑ Pollack A (26 February 2010). "Doctors Struggle to Treat Gram-Negative Bacterial Infections" . The New York Times. ISSN   0362-4331 . Retrieved 15 November 2019.
  9. ↑ Burke A Cunha (30 July 2018). John L Brusch (ed.). "Hospital-Acquired Pneumonia (Nosocomial Pneumonia) and Ventilator-Associated Pneumonia: Overview, Pathophysiology, Etiology". Webscape.
  10. ↑ Su LH, Ou JT, Leu HS, Chiang PC, Chiu YP, Chia JH, Kuo AJ, Chiu CH, Chu C (1 October 2003). "Extended Epidemic of Nosocomial Urinary Tract Infections Caused by Serratia marcescens". Journal of Clinical Microbiology. 41 (10): 4726–4732. doi: 10.1128/JCM.41.10.4726-4732.2003 . ISSN   0095-1137. PMC   254321 . PMID   14532211.
  11. ↑ Nimer NA (25 February 2022). "Nosocomial Infection and Antibiotic-Resistant Threat in the Middle East". Infection and Drug Resistance. 15: 631–639. doi: 10.2147/IDR.S351755 . ISSN   1178-6973. PMC   8887909 . PMID   35241915.
  12. ↑ Hunt J (2022). Zero. London: Swift Press. p. 71. ISBN   9781800751224.
  13. 1 2 3 4 5 6 Akbari F, Kjellerup B (2015). "Elimination of Bloodstream Infections Associated with Candida albicans Biofilm in Intravascular Catheters". Pathogens. 4 (3): 457–469. doi: 10.3390/pathogens4030457 . ISSN   2076-0817. PMC   4584267 . PMID   26131615.
  14. ↑ "Catheter-associated Urinary Tract Infections (CAUTI)". cdc.gov. 19 July 2017. Retrieved 13 January 2018.
  15. ↑ Justo JA, Bookstaver PB (2014). "Antibiotic lock therapy: review of technique and logistical challenges". Infection and Drug Resistance. 7: 343–63. doi: 10.2147/IDR.S51388 . PMC   4271721 . PMID   25548523.
  16. ↑ Jain SK, Persaud D, Perl TM, et al. (July 2005). "Nosocomial malaria and saline flush". Emerging Infect. Dis. 11 (7): 1097–9. doi: 10.3201/eid1107.050092 . PMC   3371795 . PMID   16022788.
  17. 1 2 Conway Morris A, Kohler K, De Corte T, Ercole A, De Grooth HJ, Elbers PW, Povoa P, Morais R, Koulenti D, Jog S, Nielsen N, Jubb A, Cecconi M, De Waele J, for the ESICM UNITE COVID investigators (December 2022). "Co-infection and ICU-acquired infection in COIVD-19 ICU patients: a secondary analysis of the UNITE-COVID data set". Critical Care. 26 (1): 236. doi: 10.1186/s13054-022-04108-8 . ISSN   1364-8535. PMC   9347163 . PMID   35922860.
  18. ↑ Conway Morris A, Datta D, Shankar-Hari M, Stephen J, Weir CJ, Rennie J, Antonelli J, Bateman A, Warner N, Judge K, Keenan J, Wang A, Burpee T, Brown KA, Lewis SM (May 2018). "Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study". Intensive Care Medicine. 44 (5): 627–635. doi: 10.1007/s00134-018-5247-0 . ISSN   0342-4642. PMC   6006236 . PMID   29915941.
  19. ↑ Maes M, Higginson E, Pereira-Dias J, Curran MD, Parmar S, Khokhar F, Cuchet-Lourenço D, Lux J, Sharma-Hajela S, Ravenhill B, Hamed I, Heales L, Mahroof R, Soderholm A, Forrest S (December 2021). "Ventilator-associated pneumonia in critically ill patients with COVID-19". Critical Care. 25 (1): 25. doi: 10.1186/s13054-021-03460-5 . ISSN   1364-8535. PMC   7797892 . PMID   33430915.
  20. ↑ European Centre for Disease Prevention and Control. (October 2019). "Healthcare-associated infections acquired in intensive care units. In: ECDC. Annual epidemiological report for 2017. Stockholm: ECDC; 2019" (PDF). European CDC. Retrieved 15 August 2022.
  21. ↑ Leung M, Chan AH (March 2006). "Control and management of hospital indoor air quality". Med. Sci. Monit. 12 (3): SR17–23. PMID   16501436.
  22. ↑ Chan PC, Huang LM, Lin HC, et al. (April 2007). "Control of an outbreak of pandrug-resistant Acinetobacter baumannii colonization and infection in a neonatal intensive care unit". Infect Control Hosp Epidemiol. 28 (4): 423–9. doi:10.1086/513120. PMID   17385148. S2CID   25876369.
  23. ↑ Traub-Dargatz JL, Weese JS, Rousseau JD, Dunowska M, Morley PS, Dargatz DA (July 2006). "Pilot study to evaluate 3 hygiene protocols on the reduction of bacterial load on the hands of veterinary staff performing routine equine physical examinations". Can. Vet. J. 47 (7): 671–6. PMC   1482439 . PMID   16898109.
  24. ↑ Katz JD (September 2004). "Hand washing and hand disinfection: more than your mother taught you". Anesthesiol Clin North America. 22 (3): 457–71, vi. doi:10.1016/j.atc.2004.04.002. PMID   15325713.
  25. ↑ "Statewide, All-Payer Financial Incentives Significantly Reduce Hospital-Acquired Conditions in Maryland Hospitals". Agency for Healthcare Research and Quality. 3 July 2013. Retrieved 6 July 2013.
  26. ↑ McBryde ES, Bradley LC, Whitby M, McElwain DL (October 2004). "An investigation of contact transmission of methicillin-resistant Staphylococcus aureus". Journal of Hospital Infection. 58 (2): 104–8. doi:10.1016/j.jhin.2004.06.010. PMID   15474180.
  27. ↑ Lautenbach E (2001). "Chapter 14. Impact of Changes in Antibiotic Use Practices on Nosocomial Infections and Antimicrobial Resistance—Clostridium difficile and Vancomycin-resistant Enterococcus (VRE)". In Markowitz AJ (ed.). Making Health Care Safer: A Critical Analysis of Patient Safety Practices. Agency for Healthcare Research and Quality.
  28. ↑ "Hospital Negligence Claims". PatientClaimLine.com. Retrieved 21 August 2019.
  29. ↑ Otter JA, French GL (January 2009). "Survival of nosocomial bacteria and spores on surfaces and inactivation by hydrogen peroxide vapor". J. Clin. Microbiol. 47 (1): 205–7. doi: 10.1128/JCM.02004-08 . PMC   2620839 . PMID   18971364.
  30. ↑ "Performance Feedback, Ultraviolet Cleaning Device, and Dedicated Housekeeping Team Significantly Improve Room Cleaning, Reduce Potential for Spread of Common, Dangerous Infection". Agency for Healthcare Research and Quality. 15 January 2014. Retrieved 20 January 2014.
  31. ↑ Kolár M, Urbánek K, Látal T (May 2001). "Antibiotic selective pressure and development of bacterial resistance". International Journal of Antimicrobial Agents. 17 (5): 357–363. doi:10.1016/S0924-8579(01)00317-X. ISSN   0924-8579. PMID   11337221.
  32. ↑ "The Different Methods of Sterilizing Medical Equipment". Gibraltar Laboratories. 31 May 2013. Archived from the original on 6 December 2018. Retrieved 6 December 2018.
  33. ↑ World Alliance for patient safety. WHO Guidelines on Hand Hygiene in Health Care. [ dead link ]. 2009
  34. ↑ Hugonnet S, Perneger TV, Pittet D (13 May 2002). "Alcohol-Based Handrub Improves Compliance With Hand Hygiene in Intensive Care Units". Archives of Internal Medicine. 162 (9): 1037–1043. doi: 10.1001/archinte.162.9.1037 . PMID   11996615.
  35. ↑ Haverstick, Stacy, Goodrich, Cara, Freeman, Regi, James, Shandra, Kullar, Rajkiran, Ahrens, Melissa (June 2017). "Patients' Hand Washing and Reducing Hospital-Acquired Infection". Critical Care Nurse. 37 (3): e1–e8. doi: 10.4037/ccn2017694 . PMID   28572111.
  36. ↑ Arrowsmith VA, Taylor R (4 August 2014). "Removal of nail polish and finger rings to prevent surgical infection". The Cochrane Database of Systematic Reviews. 2014 (8): CD003325. doi: 10.1002/14651858.CD003325.pub3 . PMC   7163182 . PMID   25089848.
  37. ↑ "Occupational Exposure to Bloodborne Pathogens;Needlestick and Other Sharps Injuries; Final Rule. – 66:5317–5325". Osha.gov. Retrieved 11 July 2011.
  38. ↑ Wilks S, Michels H, Keevil C (2005). "The survival of Escherichia coli O157 on a range of metal surfaces". International Journal of Food Microbiology. 105 (3): 445–454. doi:10.1016/j.ijfoodmicro.2005.04.021. PMID   16253366.
  39. ↑ Michels, H.T. (2006), Anti-Microbial Characteristics of Copper, ASTM Standardization News, October, pp. 28–31
  40. ↑ Wang M, Wei H, Zhao Y, Shang L, Di L, Lyu C, Liu J (2019). "Analysis of multidrug-resistant bacteria in 3223 patients with hospital-acquired infections (HAI) from a tertiary general hospital in China". Bosnian Journal of Basic Medical Sciences. 19 (1): 86–93. doi: 10.17305/bjbms.2018.3826 . PMC   6387671 . PMID   30579325.
  41. ↑ U.S. Department of Defense-funded clinical trials, as presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy in Washington, D.C., 28 October 2008
  42. ↑ Russotto V, Cortegiani A, Raineri SM, Giarratano A (10 December 2015). "Bacterial contamination of inanimate surfaces and equipment in the intensive care unit". Journal of Intensive Care. 3: 54. doi: 10.1186/s40560-015-0120-5 . ISSN   2052-0492. PMC   4676153 . PMID   26693023.
  43. ↑ Weber DJ, Rutala, WA (May 2013). "Self-disinfecting surfaces: review of current methodologies and future prospects". American Journal of Infection Control. 41 (5 Suppl): S31-5. doi:10.1016/j.ajic.2012.12.005. PMID   23622745.
  44. ↑ Health Quality O (2018). "Portable Ultraviolet Light Surface-Disinfecting Devices for Prevention of Hospital-Acquired Infections: A Health Technology Assessment". Ontario Health Technology Assessment Series. 18 (1): 1–73. PMC   5824029 . PMID   29487629.
  45. ↑ Weber DJ, Kanamori H, Rutala WA (August 2016). "'No touch' technologies for environmental decontamination: focus on ultraviolet devices and hydrogen peroxide systems". Current Opinion in Infectious Diseases. 29 (4): 424–31. doi:10.1097/QCO.0000000000000284. PMID   27257798. S2CID   23252531.
  46. ↑ Weber DJ, Rutala WA, Anderson DJ, Chen LF, Sickbert-Bennett EE, Boyce JM (2 May 2016). "Effectiveness of ultraviolet devices and hydrogen peroxide systems for terminal room decontamination: Focus on clinical trials". American Journal of Infection Control. 44 (5 Suppl): e77–84. doi: 10.1016/j.ajic.2015.11.015 . PMC   7132689 . PMID   27131140.
  47. 1 2 3 4 Pollack A (26 February 2010). "Rising Threat of Infections Unfazed by Antibiotics" . The New York Times. Retrieved 27 October 2022.
  48. ↑ Torres A, Ferrer M, Badia JR (2010). "Treatment Guidelines and Outcomes of Hospital-Acquired and Ventilator-Associated Pneumonia". Clinical Infectious Diseases. 51: S48–S53. doi: 10.1086/653049 . PMID   20597672.
  49. ↑ "Hospital-Acquired Pneumonia (Nosocomial Pneumonia) and Ventilator-Associated Pneumonia". 17 October 2021.
  50. ↑ Torres A, Ewig S, Lode H, Carlet J, European HAP working group (2009). "Defining, treating and preventing hospital acquired pneumonia: European perspective". Intensive Care Medicine. 35 (1): 9–29. doi: 10.1007/s00134-008-1336-9 . PMID   18989656.
  51. ↑ Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH (2001). "Experience with a clinical guideline for the treatment of ventilator-associated pneumonia". Critical Care Medicine. 29 (6): 1109–1115. doi:10.1097/00003246-200106000-00003. PMID   11395584. S2CID   19045707.
  52. ↑ "Healthcare-Associated Infections: Data Portal". US Centers for Disease Control and Prevention. 3 November 2022. Retrieved 1 August 2023.
  53. ↑ Dai T, Vrahas MS, Murray CK, Hamblin MR (February 2012). "Ultraviolet C irradiation: an alternative antimicrobial approach to localized infections?". Expert Review of Anti-infective Therapy. 10 (2): 185–95. doi:10.1586/eri.11.166. PMC   3292282 . PMID   22339192.
  54. ↑ Federaal Kenniscentrum voor de Gezondheidszorg (2009) Nosocomiale Infecties in België, deel II: Impact op Mortaliteit en Kosten. KCE-rapport 102A.
  55. ↑ Quenon JL, Gottot S, Duneton P, Lariven S, Carlet J, Régnier B, Brücker G. Enquête nationale de prévalence des infections nosocomiales en France : Hôpital Propre (octobre 1990). BEH n° 39/1993.
  56. ↑ Comité technique des infections nosocomiales (CTIN), Cellule infections nosocomiales, CClin Est, CClin Ouest, CClin Paris-Nord, CClin Sud-Est, CClin Sud-Ouest, avec la participation de 830 établissements de santé. Enquête nationale de prévalence des infections nosocomiales,1996 Archived 11 August 2009 at the Wayback Machine , BEH n° 36/1997, 2 September 1997, 4 pp.. Résumé Archived 25 September 2009 at the Wayback Machine .
  57. ↑ Lepoutre A, Branger B, Garreau N, Boulétreau A, Ayzac L, Carbonne A, Maugat S, Gayet S, Hommel C, Parneix P, Tran B pour le Réseau d'alerte, d'investigation et de surveillance des infections nosocomiales (Raisin). Deuxième enquête nationale de prévalence des infections nosocomiales, France, 2001 Archived 26 November 2009 at the Wayback Machine , Surveillance nationale des maladies infectieuses, 2001–2003. Institut de veille sanitaire, sept. 2005, 11 pp. Résumé Archived 8 August 2009 at the Wayback Machine .
  58. ↑ Institut de veille sanitaire Enquête nationale de prévalence des infections nosocomiales, France, juin 2006, Volume 1 – Méthodes, résultats, perspectives Archived 7 October 2009 at the Wayback Machine , mars 2009, ii + 81 pp. Volume 2 – Annexes Archived 7 October 2009 at the Wayback Machine , mars 2009, ii + 91 pp. Synthèse des résultats Archived 7 October 2009 at the Wayback Machine , Mars 2009, 11 pp.
  59. ↑ Institut de veille sanitaire Enquête nationale de prévalence des infections nosocomiales, France, juin 2006, Vol. 1, Tableau 31, p. 24.
  60. ↑ Réseau REA-Raisin « Surveillance des infections nosocomiales en réanimation adulte. France, résultats 2007 » Archived 12 September 2009 at the Wayback Machine , Institut de veille sanitaire, September 2009, ii + 60 pp.
  61. ↑ Vasselle, Alain « Rapport sur la politique de lutte contre les infections nosocomiales », Office parlementaire d'évaluation des politiques de santé, juin 2006, 290 pp. (III.5. Quelle est l'estimation de la mortalité attribuable aux IN ?).
  62. ↑ Lyytikainen O, Kanerva M, Agthe N, Mottonen T and the Finish Prevalence Survey Study Group. National Prevalence Survey on Nosocomial Infections in Finnish Acute Care Hospitals, 2005. 10th Epiet Scientific Seminar. Mahon, Menorca, Spain, 13–15 October 2005 [Poster].
  63. ↑ L'Italie scandalisée par "l'hôpital de l'horreur", Éric Jozsef, Libération, 17 January 2007 (in French)
  64. ↑ Lizioli A, Privitera G, Alliata E, Antonietta Banfi E, Boselli L, Panceri M, Perna M, Porretta A, Santini M, Carreri V (June 2003). "Prevalence of nosocomial infections in Italy: result from the Lombardy survey in 2000". Journal of Hospital Infection. 54 (2): 141–148. doi:10.1016/s0195-6701(03)00078-1. PMID   12818589.
  65. ↑ "Facts sheet - Swiss Hand Hygiene Campaign" (in French). Archived from the original (.doc) on 30 September 2007.
  66. ↑ Sax H, Pittet D (2005). "Résultats de l'enquête nationale de prévalence des infections nosocomiales de 2004 (snip04)". Swiss-NOSO (in French). 12 (1): 1–4. Archived from the original on 11 November 2007.
  67. 1 2 "English National Point Prevalence Survey on Healthcare-associated Infections and Antimicrobial Use, 2011" (PDF). Health Protection Agency. Archived from the original (PDF) on 8 December 2015. Retrieved 28 November 2015.
  68. ↑ Bagot M (24 October 2018). "Deadly hospital infections quadruple as staff struggle to fight superbugs". Daily Mirror. Retrieved 2 December 2018.
  69. ↑ Klevens RM, Edwards JR, Richards CL, Horan TC, Gaynes RP, Pollock DA, Cardo DM (March 2007). "Estimating Health Care-Associated Infections and Deaths in U.S. Hospitals, 2002". Public Health Reports. 122 (2): 160–166. doi: 10.1177/003335490712200205 . PMC   1820440 . PMID   17357358.
  70. ↑ Hospital-acquired infection (HAI) diagnostics market is forecasted to reach $4,386.6 million by 2023, growing at a CAGR of 7.6% during 2017–2023, P&S Intelligence
  71. ↑ Kadar N (January 2019). "Rediscovering Ignaz Philipp Semmelweis (1818–1865)". Am. J. Obstet. Gynecol. 220 (1): 26–39. doi:10.1016/j.ajog.2018.11.1084. PMID   30444981. S2CID   53567650.
  72. ↑ Pommerville J (2014). Fundamentals of microbiology. Burlington, MA: Jones & Bartlett Learning. ISBN   9781449647964.
  73. ↑ Wyklicky H, Skopec M (September–October 1983). "Ignaz Philipp Semmelweis, the prophet of bacteriology". Infect Control. 4 (5): 367–70. doi:10.1017/S0195941700059762. PMID   6354955. S2CID   25830725. Archived from the original on 4 April 2008. Retrieved 28 November 2015.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.